No significant drug−drug interaction between oral TAF‐based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT‐3 study

Abstract Introduction Concerns regarding potential drug−drug interaction (DDI) between feminizing hormone therapy (FHT) and HIV pre‐exposure prophylaxis (PrEP) may hinder PrEP use among transgender women. We assessed the potential DDI between FHT and emtricitabine‐tenofovir alafenamide (F/TAF)‐based...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Journal of the International AIDS Society
المؤلفون الرئيسيون:	Akarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, Rena Janamnuaysook, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpiroon Tawon, Jakkrapatara Boonruang, Nipat Teeratakulpisarn, Tim R. Cressey, Peter L. Anderson, Nittaya Phanuphak, the iFACT3 study team
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2025-05-01
الموضوعات:	drug−drug interactions feminizing hormone therapy HIV prevention pre‐exposure prophylaxis Thailand transgender women
الوصول للمادة أونلاين:	https://doi.org/10.1002/jia2.26502